Abstract
Amonafide (AMF), NSC 308847 is an investigational anticancer drug acting as a DNA intercalating agent. This paper presents results of a phase II clinical study of AMF in disseminated malignant melanoma. Twenty patients, eleven males and nine females, with biopsy proven malignant melanoma, performance status 0–2; median age 59 (range 29–74), and no previous chemotherapy, were treated with AMF 300 mg/m2/day by 60 min I.V. infusion for five days repeated every three weeks. Fifteen patients had lung (9 patients) and/or liver (8 patients) involvement. None had known brain metastasis at entry. All 20 patients were evaluated for response and toxicity. Six patients had stable disease and fourteen had increasing disease. With 0/20 responses, the upper 95% confidence limit for the response rate was 14%. The median survival time was 5.7 months. Hematologic toxicity was dose limiting with the incidence of leucopenia 45% and thrombocytopenia 20%. The nonhematologic toxicities included nausea and vomiting (60%), alopecia (20%), headaches (15%), diarrhea (10%), and phlebitis (10%). We conclude that AMF administered at this dose and schedule is not active in the treatment of patients with malignant melanoma, previously untreated with chemotherapy.
Similar content being viewed by others
References
Brana MF, Castellano JM, Roldan CM, Santos A, Vazquez D, Jimenez A: Synthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-11α naphtalic acid. Cancer Chemother Pharmacol 4:61–66, 1980
Brana MF, Castellano JM, Jimenez A, Lombart A, Rabadan FP, Roldan M, Roldan C, Santos A, Vazquez D: Synthesis, cytostatic activity and mode of action of a new series of imide derivatives of 3-nitro-11α naphtalic acid. Proc 10th Int Congr Chemother 1977, Current Chemother, 2:1216–1217, 1978
Brana MF, Sanz AM, Castellano JM, Roldan CM, Roldan C: Synthesis and cytostatic activity of benzo(de)isoquinolin1,3-diones. Eur J Med Chem-Chemica Therapeutica, 16:207–212, 1981
Waring MJ, Gonzalez A, Jimenez A, Vazquez D: Intercalative binding to DNA of antitumor drugs derived from 3-nitro-11α naphtalic acid. Nucleic Acids Res, 7:217–230, 1979
National Cancer Institute: Clinical Brochure, Nafidimide, NSC 308847, pp 6–22, November 1984
Saez R, Craig JB, Kuhn JG, Weiss GR, Koeller J, Phillips J, Havlin K, Harman G, Hardy J, Melink TJ, Sarosy GA, Von Hoff DD: Phase I clinical investigation of amonafide. J Clin Oncol 7:1351–1358, 1989
Legha SS, Ring S, Raber M, Felder TB, Newman RA, Krakoff IH: Phase I clinical investigation of benzisoquinolinedione. Cancer Treat Rep 71:1165–1169, 1987
Allen SL, Fusco D, Budman D, Kreis W, Weiselberg L, Lichtman S, DeMarco L, Schulman P, Vinciguerra V, Friedman E: Phase I trial of amonafide (AM) given I.V. daily × 2. Proc Am Soc Clin Oncology 10:110, 1991
Author information
Authors and Affiliations
Additional information
We thank Ms. Sheryl Johnson for secretarial assistance in preparation of this manuscript.